Vaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—(StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks ...

Delaying methotrexate by 1 month to receive the pneumococcal vaccination may not impair disease control or increase joint ...

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

While vaccinations are often linked to babies and children, adults need them just as much, especially seniors whose immune ...

Add Yahoo as a preferred source to see more of our stories on Google. NEW YORK (AP) — A scientific panel on Wednesday recommended that people 50 and older get a shot against bacteria that can cause ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported data ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

A man in his 40s who takes adalimumab for Crohn’s disease presented with a 1-day history of fever, headache and rapid onset of agitation with reduced consciousness. He was intubated, and a subsequent ...